FDA reviewers question some results from Prevnar 13 study

11/17/2009 | Reuters · Google

FDA reviewers plan to ask the advisory panel that evaluated Pfizer and Wyeth's Prevnar 13 about clinical-trial findings showing the pneumococcal vaccine missed "noninferiority" goals compared with the original version of the vaccine. Pfizer said the results demonstrate "a real and substantial benefit given [the vaccine's] demonstrated ability to elicit immune responses" to each of the 13 forms of Streptococcus pneumoniae.

View Full Article in:

Reuters · Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations